Agilent Technologies logo

Agilent Technologies

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product...

10,001+ employees

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio.

Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories.

Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life.

In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

Frequently Asked Questions

How many employees does Agilent Technologies have?

Agilent Technologies has around 10 employees. As a Biotechnology Research company, they are actively growing their team with 0 open positions.

Why should I join Agilent Technologies?

Agilent Technologies is a leading Biotechnology Research company offering exciting career opportunities. With 0 open positions, now is a great time to join their growing team.

What does Agilent Technologies do?

Agilent Technologies is a Biotechnology Research company. Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative ene...